A Study to Evaluate the the Bioequivalence of Two Different Pimicotinib Capsules in Healthy Subjects

Exclusion Criteria

• •1. Past or current medical history of chronic or severe conditions in cardiovascular, respiratory, blood, liver, kidney, gastrointestinal, endocrine or nervous systems;
• •2. Known or persistent mental disorders;
• •3. Past history of gastric or intestinal surgery, or other operations;
• •4. Dysphagia and inability to take the investigational product orally;
• •5. Intolerant to venipuncture, difficult to collect blood samples, and fear of needle sickness and blood;
• •6. Known allergy to two or more kinds of foods and drugs; or allergic to pimicotinib or its excipients; and prone to allergic reactions such as rash and urticaria;
• •7. History of infection within 30 days prior to screening;
• •8. Symptoms of fatigue and pyrexia within 2 weeks prior to screening;
• •9. Abnormal laboratory tests;
• •10. Positive result for either of the following tests: serum Hepatitis B Surface Antigen (HBsAg), Hepatitis C Virus (HCV) antibody, Human Immunodeficiency Virus (HIV) antibody, and treponema pallidum antibody;
• •11. Participated in any clinical studies of drugs as a study subject and received the study drug within 3 months prior to screening;
• •12. Previously participated in any other study related to pimicotinib and received pimicotinib;
• •13. Used strong inhibitors or inducers of CYP3A4 within 14 days prior to screening and at Screening or intending to use during the study;
• •14. Have special diet requirements and cannot accept to take a unified dietary;
• •15. Consumption of more than 14 units of alcohol per week within 3 months prior to signing the informed consent form, or a positive result for alcohol breath test on the day pre-dose, or unable to abstain from alcohol during the study;
• •16. Consumption of more than 5 cigarettes per day within 3 months prior to signing the informed consent form, or unable to abstain from tobacco products during the study;
• •17. Previous chronic consumption of excessive amount of tea, coffee, or caffeinated beverages or unable to abstain from caffeinated beverages during the study;
• •18. Known history of drug abuse or positive for drug abuse screening test;
• •19. Used over the counter or prescription drugs within 14 days prior to screening, or plan to use such drugs during the study;
• •20. Donated or lost \> 400 mL of blood within 3 months prior to screening; received blood transfusions or used blood products within 2 months prior to screening;
• •21. Received vaccine within 2 months prior to screening, or plan to get vaccinated during the study;
• •22. Significant abnormalities and judged by the investigator as clinical significance in vital signs;
• •23. Heart rate-corrected QT interval prolongation;
• •24. Subjects involved in the design or conduct of this study and their immediate family members;
• •25. Subjects who, in the opinion of the investigator, are not suitable for enrollment or may not be able to complete the study for other reasons.